Skip to content

02877.HK

China Shineway Pharmaceutical Group Limited

HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN

HKD 7.51
+3.09%
Ask drillr

Year over year

Reported trailing growth

Revenue
-20.8%
EBITDA
+0.1%
EBIT
-0.0%
EPS
-3.7%
Free cash flow
+11.6%
Operating cash flow
+10.5%

Forward estimates

Based on analyst estimates

Revenue
-55.9%
EBITDA
—
EPS
—

Three-year CAGR

Revenue
-7.4%
EBITDA
-12.0%
EBIT
-1.5%
Net income
+9.5%
EPS
+9.5%
Free cash flow
-0.2%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026